Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells
about
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinibCritical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cellsDual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.Investigating mammalian target of rapamycin inhibitors for their anticancer properties.Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa?Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemiaBeta interferon regulation of glucose metabolism is PI3K/Akt dependent and important for antiviral activity against coxsackievirus B3.Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.Targeting the mTOR Pathway in Leukemia.Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.Activation of protein kinase C{eta} by type I interferonsRegulatory effects of programmed cell death 4 (PDCD4) protein in interferon (IFN)-stimulated gene expression and generation of type I IFN responses.A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals.Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling.Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells.
P2860
Q33707394-D99E62F1-3083-460E-B8A9-FC9E0311340DQ34004994-A9EB6687-5F6C-4D07-A395-591AA9895D51Q34260622-3D0F29E0-5F59-48CD-B647-05DBBFD1EA40Q35048118-FC9F7263-2D4C-4E18-9491-B1912A8EA591Q35091507-10E26DB0-B4E5-44FB-83C9-B5617B10D626Q35608171-60D9B53B-DB31-43BE-A77F-90D8A75857CAQ35753251-E6F6570F-C7BB-49E9-9C1A-376D8752FB87Q36600294-786F77EB-3B24-4AFE-AA7E-1FCFA9091FFEQ36749168-A2ABFF5B-FEDE-49AA-8EC5-4D8D6775FBA3Q36893107-54C670E2-108F-4A1D-9EA1-80C53119EB63Q37288747-EE20721F-A935-494A-9088-BAE3AA10066FQ37643727-F16C27EE-D105-4E47-B890-8E14682E9FEBQ37779489-13941970-A6E6-42B3-AD73-D687072C6D1CQ37836928-489B970B-9CB6-4DAE-854D-32F99FD2346BQ37836931-5F0D229A-5195-44EA-9D54-1F17FCDBC2E2Q37976243-CE60918B-ADAC-4B9C-9770-97F9DA6AA846Q38094782-FDF7789A-D3A4-4B6A-9E85-2591F41D4E7BQ38790630-741AD851-0D34-4873-8660-E5095625FBB6Q38923281-254F7D3D-463A-4891-8F1D-7DB894739EE3Q39010100-BD39EF7D-0A40-4749-BBE1-D73DAFD7B22AQ39813618-C8EB7E79-4A02-4A4C-9A1B-A9B1CB06DE11Q39884881-50AB5CFF-AD21-44F6-9DCE-494B9A4C0600Q42270443-65DF1D1C-5352-4F19-8B10-DD585EBDC500Q42424512-AD69A5FF-F6EA-431C-8ED8-05D83D304204Q42807577-60A8074C-332D-446F-B675-CAA0174CB142Q43127521-218B99A7-E3D2-4131-8634-9F4455B71EFFQ46874668-D207CB37-6869-4955-AC16-23556CD83269Q53587646-9C638D35-ECAE-43F9-A7D8-ED55618E1571Q54517713-2BF4ADE6-4C6D-4A13-997E-C79D657E1B96
P2860
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Differential regulation of the ...... nic myelogenous leukemia cells
@en
type
label
Differential regulation of the ...... nic myelogenous leukemia cells
@en
prefLabel
Differential regulation of the ...... nic myelogenous leukemia cells
@en
P2093
P2860
P1433
P1476
Differential regulation of the ...... nic myelogenous leukemia cells
@en
P2093
Antonella Sassano
Beata Majchrzak
Efstratios Katsoulidis
Elizabeth A Eklund
Jessica Smith
Leonidas C Platanias
Shahab Uddin
Simrit Parmar
Suman Kambhampati
P2860
P304
P356
10.1182/BLOOD-2004-10-4003
P407
P577
2005-03-24T00:00:00Z